Metformin in Pemphigus Vulgaris

Pilot Study of the Efficacy of Metformin as an Adjuvant Therapy in Patients with Pemphigus Vulgaris

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170822035834N2

Enrollment

Registered

2018-03-05

Start date

2018-04-04

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Pemphigus Vulgaris. Condition 2: Pemphigus foliaceus. Diseases of the skin and subcutaneous tissue Diseases of the skin and subcutaneous tissue

Interventions

Intervention 1: Intervention group: Metformin HEXAL (Raha-Isfahan Pharmaceutical Company) receiving a dose of 2000 mg / day, divided into 1000 mg every 12 hours for three months. Intervention 2: Contr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: People diagnosed with their disease, and clinical manifestations and laboratory findings related to pemphigus (skin manifestations, etc.) have been proven by a dermatologist. And hospitalized in the relevant department. Individual consent to participate in the study age more than 18

Exclusion criteria

Exclusion criteria: age less than 18 Duration of diagnosis is more than 24 months.

Design outcomes

Primary

Measure	Time frame
IgG1: Measuring the amount of these factors in order to evaluate the role of metformin in the improvement of pemphigus. Timepoint: Before the intervention (at the beginning of the study) and after the intervention (three months after receiving metformin). Method of measurement: Immunological ELISA kits.;IgG4: Measuring the amount of these factors in order to evaluate the role of metformin in the improvement of pemphigus. Timepoint: Before the intervention (at the beginning of the study) and after the intervention (three months after receiving metformin). Method of measurement: Immunological ELISA kits.;NFkB: Measuring the amount of these factors in order to evaluate the role of metformin in the improvement of pemphigus. Timepoint: Before the intervention (at the beginning of the study) and after the intervention (three months after receiving metformin). Method of measurement: Immunological ELISA kits.;TNFa: Measuring the amount of these factors in order to evaluate the role of metformin in the improvement of pemphigus. Timepoint: Before the intervention (at the beginning of the study) and after the intervention (three months after receiving metformin). Method of measurement: Immunological ELISA kits.	—

Measure

Time frame

IgG1: Measuring the amount of these factors in order to evaluate the role of metformin in the improvement of pemphigus. Timepoint: Before the intervention (at the beginning of the study) and after the intervention (three months after receiving metformin). Method of measurement: Immunological ELISA kits.;IgG4: Measuring the amount of these factors in order to evaluate the role of metformin in the improvement of pemphigus. Timepoint: Before the intervention (at the beginning of the study) and after the intervention (three months after receiving metformin). Method of measurement: Immunological ELISA kits.;NFkB: Measuring the amount of these factors in order to evaluate the role of metformin in the improvement of pemphigus. Timepoint: Before the intervention (at the beginning of the study) and after the intervention (three months after receiving metformin). Method of measurement: Immunological ELISA kits.;TNFa: Measuring the amount of these factors in order to evaluate the role of metformin in the improvement of pemphigus. Timepoint: Before the intervention (at the beginning of the study) and after the intervention (three months after receiving metformin). Method of measurement: Immunological ELISA kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Gholamreza Houshmand

Sari University of Medical Sciences

g.houshmand@mazums.ac.ir+98 11 3354 3081

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026